Search

Your search keyword '"Daniel, Davey"' showing total 182 results
Start Over Author "Daniel, Davey"
182 results on '"Daniel, Davey"'

3. Treatment (Tx) inequities in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) harboring actionable driver oncogenes (ADO) in the first-line (1L) setting.

Author

Vidal, Gregory A., primary, Stricker, Thomas, additional, Ma, Esprit, additional, Yu, Elaine, additional, Xia, Zhiyu, additional, Sheinson, Daniel, additional, Sincan, Murat, additional, Huang, Richard S. P., additional, Lin, Victor T. G., additional, Zuniga, Richard Michael, additional, Jain, Neha M., additional, Martin, Richard Lewis, additional, and Daniel, Davey B., additional

Published
2024
Full Text
View/download PDF

10. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial

Author

Spigel, David R., Jotte, Robert M., Aix, Santiago Ponce, Gressot, Laurent, Morgensztern, Daniel, McCleod, Michael, Socinski, Mark A., Daniel, Davey, Juan-Vidal, Oscar, Mileham, Kathryn F., West, Howard, Page, Ray, Reinmuth, Niels, Knoble, Jeanna, Chen, Tianlei, Bhore, Rafia, Wolfsteiner, Marianne, Ong, Teng Jin, Gridelli, Cesare, and Thomas, Michael

Published
2021
Full Text
View/download PDF

11. Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes.

Author

Stricker, Thomas, Jain, Neha, Ma, Esprit, Yu, Elaine, Wang, Rongrong, Schuldt, Robert, Price, Richard, Szado, Tania, Sussell, Jesse, Ogale, Sarika, Lin, Victor, Arrowsmith, Edward, Slater, Dennis, Vaena, Daniel, Staszewski, Harry, Fang, Bruno, Seneviratne, Lasika, and Daniel, Davey

Subjects
RESEARCH funding, MULTIPLE regression analysis, RETROSPECTIVE studies, TUMOR markers, DESCRIPTIVE statistics, TREATMENT effectiveness, ONCOGENES, ELECTRONIC health records, LUNG cancer, PROGRESSION-free survival, TIME, PROPORTIONAL hazards models, SEQUENCE analysis
Abstract

Background A recent real-world study observed that 24% of patients with advanced non–small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADOs) initiated nontargeted therapies before biomarker test results became available. This study assessed the clinical impact of the timing of first-line (1L) targeted therapies (TTs) in aNSCLC. Materials and Methods This retrospective analysis of a nationwide electronic health record–derived deidentified database included patients aged ≥18 years diagnosed with aNSCLC with ADOs (ALK, BRAF, EGFR, RET, MET, ROS-1, and NTRK) from January 1, 2015, to October 18, 2022, by biomarker testing within 90 days after advanced diagnosis and received 1L treatment. Cohorts were defined by treatment patterns ≤42 days after test results: "Upfront TT" received 1L TT ≤42 days; "Switchers" initiated 1L non-TT before or after testing but switched to TT ≤42 days; and "Non-switchers" initiated non-TT before or after testing and did not switch at any time. Adjusted multivariate Cox regression evaluated real-world progression-free survival, real-world time to next treatment or death, and real-world overall survival. Results A total of 3540 patients met the study criteria; 78% were treated in a community setting, and 50% underwent next-generation sequencing (NGS). There was no significant difference in outcomes between Switchers and Upfront TT; inferior outcomes were observed in Non-switchers versus Upfront TT. Conclusion Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting

Author

Vidal, Gregory A., primary, Jain, Neha, additional, Fisher, Aaron, additional, Sheinson, Daniel, additional, Lofgren, Katherine T., additional, Ma, Esprit, additional, Yu, Elaine, additional, Comment, Leah, additional, Miksad, Rebecca, additional, Sincan, Murat, additional, Martin, Richard Lewis, additional, Zuniga, Richard, additional, and Daniel, Davey, additional

Published
2024
Full Text
View/download PDF

13. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Author

Hui, Rina, Özgüroğlu, Mustafa, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Yokoi, Takashi, Chiappori, Alberto, Lee, Ki Hyeong, de Wit, Maike, Cho, Byoung Chul, Gray, Jhanelle E, Rydén, Anna, Viviers, Louis, Poole, Lynne, Zhang, Yiduo, Dennis, Phillip A, and Antonia, Scott J

Published
2019
Full Text
View/download PDF

14. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

Author

Spigel, David R., McCleod, Michael, Jotte, Robert M., Einhorn, Lawrence, Horn, Leora, Waterhouse, David M., Creelan, Ben, Babu, Sunil, Leighl, Natasha B., Chandler, Jason C., Couture, Felix, Keogh, George, Goss, Glenwood, Daniel, Davey B., Garon, Edward B., Schwartzberg, Lee S., Sen, Rohini, Korytowsky, Beata, Li, Ang, Aanur, Nivedita, and Hussein, Maen A.

Published
2019
Full Text
View/download PDF

15. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Author

West, Howard, McCleod, Michael, Hussein, Maen, Morabito, Alessandro, Rittmeyer, Achim, Conter, Henry J, Kopp, Hans-Georg, Daniel, Davey, McCune, Steven, Mekhail, Tarek, Zer, Alona, Reinmuth, Niels, Sadiq, Ahad, Sandler, Alan, Lin, Wei, Ochi Lohmann, Tania, Archer, Venice, Wang, Lijia, Kowanetz, Marcin, and Cappuzzo, Federico

Published
2019
Full Text
View/download PDF

16. Supplementary Appendix from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Author

Cascone, Tina, primary, Kar, Gozde, primary, Spicer, Jonathan D., primary, García-Campelo, Rosario, primary, Weder, Walter, primary, Daniel, Davey B., primary, Spigel, David R., primary, Hussein, Maen, primary, Mazieres, Julien, primary, Oliveira, Julio, primary, Yau, Edwin H., primary, Spira, Alexander I., primary, Anagnostou, Valsamo, primary, Mager, Raymond, primary, Hamid, Oday, primary, Cheng, Lin-Yang, primary, Zheng, Ying, primary, Blando, Jorge, primary, Tan, Tze Heng, primary, Surace, Michael, primary, Rodriguez-Canales, Jaime, primary, Gopalakrishnan, Vancheswaran, primary, Sellman, Bret R., primary, Grenga, Italia, primary, Soo-Hoo, Yee, primary, Kumar, Rakesh, primary, McGrath, Lara, primary, and Forde, Patrick M., primary

Published
2023
Full Text
View/download PDF

17. Data from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Author

Cascone, Tina, primary, Kar, Gozde, primary, Spicer, Jonathan D., primary, García-Campelo, Rosario, primary, Weder, Walter, primary, Daniel, Davey B., primary, Spigel, David R., primary, Hussein, Maen, primary, Mazieres, Julien, primary, Oliveira, Julio, primary, Yau, Edwin H., primary, Spira, Alexander I., primary, Anagnostou, Valsamo, primary, Mager, Raymond, primary, Hamid, Oday, primary, Cheng, Lin-Yang, primary, Zheng, Ying, primary, Blando, Jorge, primary, Tan, Tze Heng, primary, Surace, Michael, primary, Rodriguez-Canales, Jaime, primary, Gopalakrishnan, Vancheswaran, primary, Sellman, Bret R., primary, Grenga, Italia, primary, Soo-Hoo, Yee, primary, Kumar, Rakesh, primary, McGrath, Lara, primary, and Forde, Patrick M., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data - Supplementary Table 7 from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Author

Cascone, Tina, primary, Kar, Gozde, primary, Spicer, Jonathan D., primary, García-Campelo, Rosario, primary, Weder, Walter, primary, Daniel, Davey B., primary, Spigel, David R., primary, Hussein, Maen, primary, Mazieres, Julien, primary, Oliveira, Julio, primary, Yau, Edwin H., primary, Spira, Alexander I., primary, Anagnostou, Valsamo, primary, Mager, Raymond, primary, Hamid, Oday, primary, Cheng, Lin-Yang, primary, Zheng, Ying, primary, Blando, Jorge, primary, Tan, Tze Heng, primary, Surace, Michael, primary, Rodriguez-Canales, Jaime, primary, Gopalakrishnan, Vancheswaran, primary, Sellman, Bret R., primary, Grenga, Italia, primary, Soo-Hoo, Yee, primary, Kumar, Rakesh, primary, McGrath, Lara, primary, and Forde, Patrick M., primary

Published
2023
Full Text
View/download PDF

19. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Author

Cascone, Tina, primary, Kar, Gozde, additional, Spicer, Jonathan D., additional, García-Campelo, Rosario, additional, Weder, Walter, additional, Daniel, Davey B., additional, Spigel, David R., additional, Hussein, Maen, additional, Mazieres, Julien, additional, Oliveira, Julio, additional, Yau, Edwin H., additional, Spira, Alexander I., additional, Anagnostou, Valsamo, additional, Mager, Raymond, additional, Hamid, Oday, additional, Cheng, Lin-Yang, additional, Zheng, Ying, additional, Blando, Jorge, additional, Tan, Tze Heng, additional, Surace, Michael, additional, Rodriguez-Canales, Jaime, additional, Gopalakrishnan, Vancheswaran, additional, Sellman, Bret R., additional, Grenga, Italia, additional, Soo-Hoo, Yee, additional, Kumar, Rakesh, additional, McGrath, Lara, additional, and Forde, Patrick M., additional

Published
2023
Full Text
View/download PDF

20. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA

Author

Schwartzberg, Lee, primary, Daniel, Davey, additional, Vaena, Daniel, additional, Slater, Dennis, additional, Staszewski, Harry, additional, Fang, Bruno, additional, Seneviratne, Lasika, additional, Yu, Elaine, additional, Price, Richard, additional, Szado, Tania, additional, Meyer, Craig S, additional, Shah, Anuj, additional, and Ma, Esprit, additional

Published
2023
Full Text
View/download PDF

22. Supplementary Table Legends from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Author

Leighl, Natasha B., primary, Page, Ray D., primary, Raymond, Victoria M., primary, Daniel, Davey B., primary, Divers, Stephen G., primary, Reckamp, Karen L., primary, Villalona-Calero, Miguel A., primary, Dix, Daniel, primary, Odegaard, Justin I., primary, Lanman, Richard B., primary, and Papadimitrakopoulou, Vassiliki A., primary

Published
2023
Full Text
View/download PDF

23. Case Study: Transition to a Vegan Diet in an Elite Male Gaelic Football Player

Author

Daniel Davey, Shane Malone, and Brendan Egan

Subjects
athlete, body composition, field sport, running speed, plant-based, Sports, GV557-1198.995
Abstract

Vegan diets are increasingly of interest to athletes, but require a well-planned approach in order to mitigate the risk of potential adverse effects on nutrient intakes, and consequently performance. This case study reports the process of an elite male Gaelic football player (age 25 years; height, 1.88 m; body mass, 87.8 kg; lean body mass, 73.26 kg; body fat, 11.3%) transitioning from an omnivorous diet to a vegan diet at the beginning of a competitive season. The report encompasses key considerations in the planning and provision of nutrition support in this context, in addition to iterations needed based on challenges presented by the athlete. Analysis of nutrient intake (Nutritics Dietary Analysis Software), body composition (dual X-ray absorptiometry; Lunar iDXA, GE Healthcare), and running performance during match-play (global positioning system-based tracking; STATSports Apex) each indicated that with adequate knowledge and education, and appropriate planning, commitment and iterative feedback, the athlete was able to meet nutrition targets on a vegan diet without compromising key performance indicators compared to the omnivorous diet of the previous season. We anticipate that this case study will assist practitioners to recognize the key considerations to address when working with athletes transitioning to a vegan diet.

Published
2021
Full Text
View/download PDF

25. Abstract 2267: Biomarker testing and treatment (tx) patterns in a large community oncology network

Author

Ma, Esprit, primary, Yu, Elaine, additional, Szado, Tania, additional, Price, Richard, additional, Meyer, Craig S., additional, Shah, Anuj, additional, Yang, Baiyu, additional, Vaena, Daniel, additional, Daniel, Davey, additional, Slater, Dennis, additional, Staszewski, Harry, additional, Fang, Bruno, additional, Seneviratne, Lasika, additional, and Schwartzberg, Lee, additional

Published
2022
Full Text
View/download PDF

26. Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)

Author

Cascone, Tina, primary, García-Campelo, Rosario, additional, Spicer, Jonathan, additional, Weder, Walter, additional, Daniel, Davey, additional, Spigel, David, additional, Hussein, Maen, additional, Mazieres, Julien, additional, Oliveira, Julio, additional, Yau, Edwin, additional, Spira, Alexander, additional, Mager, Raymond, additional, Hamid, Oday, additional, Cheng, Lin-Yang, additional, Zheng, Ying, additional, Blando, Jorge, additional, McGrath, Lara, additional, Grenga, Italia, additional, Soo-Hoo, Yee, additional, Kumar, Rakesh, additional, and Forde, Patrick, additional

Published
2022
Full Text
View/download PDF

27. Evolution of biomarker testing in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC) in U.S. community practices.

Author

Schwartzberg, Lee S., primary, Yu, Elaine, additional, Meyer, Craig S., additional, Shah, Anuj, additional, Price, Richard, additional, Szado, Tania, additional, Vaena, Daniel A., additional, Daniel, Davey B., additional, Slater, Dennis, additional, Staszewski, Harry, additional, Fang, Bruno, additional, Seneviratne, Lasika, additional, and Ma, Esprit, additional

Published
2022
Full Text
View/download PDF

28. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Author

Antonia, Scott J., Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Yokoi, Takashi, Chiappori, Alberto, Lee, Ki H., de Wit, Maike, Cho, Byoung C., Bourhaba, Maryam, Quantin, Xavier, Tokito, Takaaki, Mekhail, Tarek, Planchard, David, Kim, Young-Chul, Karapetis, Christos S., Hiret, Sandrine, Ostoros, Gyula, Kubota, Kaoru, Gray, Jhanelle E., Paz-Ares, Luis, de Castro Carpeño, Javier, Wadsworth, Catherine, Melillo, Giovanni, Jiang, Haiyi, Huang, Yifan, Dennis, Phillip A., and Özgüroğlu, Mustafa

Published
2017
Full Text
View/download PDF

29. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients with Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)

Author

Yardley, Denise A., primary, Young, Robyn R., additional, Adelson, Kerin B., additional, Silber, Andrea L., additional, Najera, Jose E., additional, Daniel, Davey B., additional, Peacock, Nancy, additional, Finney, Lindsey, additional, Hoekstra, Susan J., additional, Shastry, Mythili, additional, Hainsworth, John D., additional, and Burris, Howard A., additional

Published
2021
Full Text
View/download PDF

30. Body Mass and Body Composition Changes over 7 Years in a Male Professional Rugby Union Team

Author

Daniel Davey, Karen Hind, Gareth Farrell, Fiona Wilson, Cliodhna McHugh, and Aoife O'Halloran

Subjects
Adult, Male, Physical Therapy, Sports Therapy and Rehabilitation, Body fat percentage, Fat mass, Body Mass Index, 03 medical and health sciences, 0302 clinical medicine, Lower body, Absorptiometry, Photon, Reduced fat, medicine, Humans, Orthopedics and Sports Medicine, 030212 general & internal medicine, Longitudinal Studies, Dual-energy X-ray absorptiometry, medicine.diagnostic_test, business.industry, Mean age, 030229 sport sciences, Lean body mass, Body Composition, Rugby, Seasons, business, Body mass index, human activities, Demography
Abstract

The purpose of this study was to investigate longitudinal body mass and body composition changes in one professional rugby union team (n=123), (i) according to position [forwards (n=58) versus backs (n=65)], analysis of players with 6 consecutive seasons of DXA scans (n=21) and, (iii) to examine differences by playing status [academy and international], over 7 years. Players [mean age: 26.8 y, body mass index: 28.9+kg.m2] received DXA scans at fourtime points within each year. A modest (but non-significant) increase in mean total mass (0.8 kg) for professional players was reflected by increased lean mass and reduced body fat mass. At all-time points, forwards had a significantly greater total mass, lean mass and body fat percentage compared to backs (p

Published
2021

31. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

Author

Gray, Jhanelle E., Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki Hyeong, Cho, Byoung Chul, Planchard, David, Paz-Ares, Luis, Faivre-Finn, Corinne, Vansteenkiste, Johan F., Spigel, David R., Wadsworth, Catherine, Taboada, Maria, Dennis, Phillip A., Özgüroğlu, Mustafa, and Antonia, Scott J.

Published
2020
Full Text
View/download PDF

33. Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

Author

Page, Ray D., primary, Drusbosky, Leylah, additional, Dada, Hiba I., additional, Raymond, Victoria M., additional, Daniel, Davey B., additional, Divers, Stephen G., additional, Reckamp, Karen L., additional, Villalona-Calero, Miguel Angel, additional, Odegaard, Justin Iver, additional, Lanman, Richard B., additional, Papadimitrakopoulou, Vassiliki, additional, and Leighl, Natasha B., additional

Published
2021
Full Text
View/download PDF

34. Impact of clinical trial enrollment on episode costs in the Oncology Care Model (OCM).

Author

Young, Garrett, primary, Bilbrey, Larry Edward, additional, Arrowsmith, Edward, additional, Blakely, L. Johnetta, additional, Daniel, Davey B., additional, Yue, Andrew, additional, Chaudhry, Basit Iqbal, additional, Spigel, David R., additional, Lyss, Aaron J., additional, Dickson, Natalie R., additional, Fox, John, additional, Schleicher, Stephen Matthew, additional, and Schwartzberg, Lee S., additional

Published
2021
Full Text
View/download PDF

35. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

Author

Garassino, Marina C, primary, Paz-Ares, Luis, additional, Hui, Rina, additional, Faivre-Finn, Corinne, additional, Spira, Alex, additional, Planchard, David, additional, Özgüroğlu, Mustafa, additional, Daniel, Davey, additional, Vicente, David, additional, Murakami, Shuji, additional, Langer, Corey, additional, Senan, Suresh, additional, Spigel, David, additional, Rydén, Anna, additional, Zhang, Yiduo, additional, O'Brien, Cathy, additional, Dennis, Phillip A, additional, and Antonia, Scott J, additional

Published
2021
Full Text
View/download PDF

36. A career in sport does not eliminate risk of cardiovascular disease : a systematic review and meta-analysis of the cardiovascular health of field-based athletes

Author

Fiona Wilson, Daniel Davey, Karen Hind, Joice Cunningham, and Cliodhna McHugh

Subjects
Gerontology, American football, Blood Pressure, Physical Therapy, Sports Therapy and Rehabilitation, Football, Disease, Risk Factors, Prevalence, medicine, Humans, Orthopedics and Sports Medicine, Anthropometry, Career Choice, biology, Athletes, business.industry, biology.organism_classification, medicine.disease, Blood pressure, Cardiovascular Diseases, Meta-analysis, business, Biomarkers, Dyslipidemia, Sports
Abstract

Objectives To determine the prevalence of cardiovascular disease (CVD) risk factors in current field-based athletes. Design Meta-analysis. Methods This review was conducted and reported in accordance with PRISMA and pre-registered with PROSPERO. Articles were retrieved via online database search engines, with no date or language restriction. Studies investigating current field-based athletes (>18years) for CVD risk factors according to the European Society of Cardiology and American Heart Association were screened. Full texts were screened using Covidence and Cochrane criteria. Eligible articles were critically appraised using the AXIS tool. Individual study estimates were assessed by random-effect meta-analyses to examine the overall effect. Results This study was ascribed a 1b evidence level, according to the Oxford Centre for Evidence-based Medicine. 41 studies were identified, including 5546 athletes from four sports; American football; soccer; rugby and baseball mean ages: 18–28. Despite participation in sport, increased body mass was associated with increased total cholesterol, low-density lipoprotein, triglycerides, hypertension, systolic blood pressure, and decreased high-density lipoprotein. Linemen had increased prevalence of hypertension compared to non-athletes. Conflicting findings on fasting glucose were prevalent. There were inconsistencies in screening and reporting of CVD risk factors. Sport specific anthropometric demands were associated with elevated prevalence of CVD risk factors, most notably: elevated body mass; dyslipidemia; elevated systolic blood pressure and; glucose. Conclusions There are elevated levels of risk for CVD in some athletes, primarily football players. Lifestyle behaviours associated with elite athleticism, particularly football linemen potentially expose players to greater metabolic and CVD risk, which is not completely offset by sport participation.

Published
2020

37. Increases in DXA-Derived Visceral Fat Across One Season in Professional Rugby Union Players: Importance of Visceral Fat Monitoring in Athlete Body Composition Assessment

Author

Cliodhna McHugh, Fiona Wilson, Jason Wyse, Karen Hind, and Daniel Davey

Subjects
0301 basic medicine, Adult, Male, Endocrinology, Diabetes and Metabolism, Football, Adipose tissue, 030209 endocrinology & metabolism, Intra-Abdominal Fat, Body fat percentage, Low grade inflammation, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Animal science, Absorptiometry, Photon, Bone Density, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Orthopedics and Sports Medicine, Visceral fat, Dual-energy X-ray absorptiometry, medicine.diagnostic_test, business.industry, nutritional and metabolic diseases, Total body, Linear relationship, Athletes, Lean body mass, Body Composition, 030101 anatomy & morphology, Seasons, business, human activities
Abstract

Introduction: In rugby, the average player body mass has increased by approximately 25% since 1955. Visceral adipose tissue (VAT) is associated with low grade inflammation, and chronic diseases, such as cardiovascular diseases. The purpose of this study was to investigate changes in VAT in relation to other indices of body composition, across 1 season in professional rugby. Methodology: One hundred and sixteen male rugby union players’ (age: 26.2 ± 4.6 y, BMI: 29.40 ± 3.22 kg.m2) total body composition dual energy X-ray absorptiometry scans from 4 time points across the season (baseline, preseason, midseason, and postseason) were analyzed. Players were grouped by playing position, forwards (n = 65) and backs (n = 51). Players followed individually tailored diet plans. Results: Mean baseline VAT was 404.67 ± 229.43 g (forwards: 469.36 ± 263.16 g, backs: 311.40 ± 121.15 g). Total mass, lean mass, body fat percentage (%BF), and VAT were greater in forwards than backs at all 4 timepoints. Meaningful increases in VAT across the season, were observed in 37.5% of backs and 53.6% of forwards. There was a positive linear relationship between lean mass and total mass, up to 116.04 kg total mass. Beyond this threshold, lean mass accumulation reduced and %BF and VAT mass increased. There were significant relationships between %BF, VAT, and BMI (p < 0.001), but no physiological relevant pattern was discerned. Conclusions: Despite regular high-intensive exercise and individually tailored dietary control across a professional rugby season, players from both playing positions demonstrated increases in VAT, although the cause remains unknown. Our findings indicate the importance of monitoring VAT in athletes alongside standard measures of body composition. Additionally, our findings suggest there may be an upper threshold of body mass beyond which lean mass may not increase further and instead %BF and VAT are more likely to accumulate. Further research is required to identify how increasing player size may impact long-term cardiometabolic health given the known links between VAT and cardiometabolic risk.

Published
2020

38. Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC

Author

Gray, Jhanelle E., Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki Hyeong, Cho, Byoung Chul, Planchard, David, Paz-Ares, Luis, Faivre-Finn, Corinne, Vansteenkiste, Johan F., Spigel, David R., Wadsworth, Catherine, Taboada, Maria, Dennis, Phillip A., Özgüroğlu, Mustafa, and Antonia, Scott J.

Subjects
PACIFIC, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Overall survival, Three-year update, Durvalumab, NSCLC
Abstract

BACKGROUND In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.42-65; P

Published
2020

40. Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC)

Author

Yardley, Denise A, primary, Young, Robyn R, additional, Adelson, Kerin B, additional, Silber, Andrea L, additional, Kommor, Michael D, additional, Najera, Jose E, additional, Daniel, Davey B, additional, Peacock, Nancy W, additional, Shastry, Mythili, additional, Hainsworth, John D, additional, and Burris, Howard A, additional

Published
2021
Full Text
View/download PDF

41. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled PhaseIItrial

Author

Daniel, Davey, primary, Kuchava, Vladimer, additional, Bondarenko, Igor, additional, Ivashchuk, Oleksandr, additional, Reddy, Sreekanth, additional, Jaal, Jana, additional, Kudaba, Iveta, additional, Hart, Lowell, additional, Matitashvili, Amiran, additional, Pritchett, Yili, additional, Morris, Shannon R., additional, Sorrentino, Jessica A., additional, Antal, Joyce M., additional, and Goldschmidt, Jerome, additional

Published
2021
Full Text
View/download PDF

42. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)

Author

Faivre-Finn, Corinne, primary, Spigel, David R., additional, Senan, Suresh, additional, Langer, Corey, additional, Perez, Bradford A., additional, Özgüroğlu, Mustafa, additional, Daniel, Davey, additional, Villegas, Augusto, additional, Vicente, David, additional, Hui, Rina, additional, Murakami, Shuji, additional, Paz-Ares, Luis, additional, Broadhurst, Helen, additional, Wadsworth, Catherine, additional, Dennis, Phillip A., additional, and Antonia, Scott J., additional

Published
2021
Full Text
View/download PDF

43. Eat Up The Next Level : Perform at Your Best Physically + Mentally Every Day

Author

Daniel Davey and Daniel Davey

Abstract

Bring your health and performance to the next level. Next level eating means prioritising food in your routine. It means understanding the power that food has to nourish, heal, support and energise your body. Daniel Davey is a performance nutritionist who has helped Ireland's most successful athletes raise their game. In this book, Daniel draws on everything he has learned in order to demonstrate the science of how food can help us perform at our best physically and mentally every day. The recipes in this cookbook are simple, delicious, nutrition-packed and uniquely designed to help you unlock the key to an enhanced life. They can be used to support specific training goals, to help you recover from injury or if you are in need of an immune system boost. Daniel also reveals how he has helped his top clients develop the right mindset to make consistently good food and lifestyle choices – and reap the rewards. This is a transformative cookbook that will bring your health and performance to the next level.

Published
2022

44. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

Author

Waterhouse, David M., primary, Garon, Edward B., additional, Chandler, Jason, additional, McCleod, Michael, additional, Hussein, Maen, additional, Jotte, Robert, additional, Horn, Leora, additional, Daniel, Davey B., additional, Keogh, George, additional, Creelan, Ben, additional, Einhorn, Lawrence H., additional, Baker, Justin, additional, Kasbari, Samer, additional, Nikolinakos, Petros, additional, Babu, Sunil, additional, Couture, Felix, additional, Leighl, Natasha B., additional, Reynolds, Craig, additional, Blumenschein, George, additional, Gunuganti, Vijay, additional, Li, Ang, additional, Aanur, Nivedita, additional, and Spigel, David R., additional

Published
2020
Full Text
View/download PDF

46. Finding value in social media: A collaborative online communication platform linking providers to education and an online tumor board across a large community of oncology practices.

Author

Daniel, Davey B., primary, Blakely, Johnetta, additional, Schleicher, Stephen Matthew, additional, Allen, Duncan, additional, Marsden, Mary Catherine, additional, Arrowsmith, Mary Margaret, additional, Grothey, Axel, additional, and Schwartzberg, Lee S., additional

Published
2020
Full Text
View/download PDF

47. Abstract CT213: Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC)

Author

Planchard, David, primary, Özgüroğlu, Mustafa, additional, Daniel, Davey, additional, Villegas, Augusto, additional, Vicente, David, additional, Murakami, Shuji, additional, Hui, Rina, additional, Faivre-Finn, Corinne, additional, Paz-Ares, Luis, additional, Wu, Yi-Long, additional, Macpherson, Euan, additional, Newton, Michael, additional, Dennis, Phillip, additional, and Antonia, Scott J., additional

Published
2020
Full Text
View/download PDF

48. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Author

Bedrose, Sara, primary, Miller, Kevin Charles, additional, Altameemi, Lina, additional, Ali, Mohamed S, additional, Nassar, Sameh, additional, Garg, Naveen, additional, Daher, Marilyne, additional, Eaton, Keith D, additional, Yorio, Jeffrey Thomas, additional, Daniel, Davey B, additional, Campbell, Matthew, additional, Bible, Keith C, additional, Ryder, Mabel, additional, Chintakuntlawar, Ashish V, additional, and Amir Habra, Mouhammed, additional

Published
2020
Full Text
View/download PDF

50. Cardiovascular health of retired field-based athletes : a systematic review and meta-analysis

Author

Daniel Davey, Fiona Wilson, Karen Hind, and Cliodhna McHugh

Subjects
Gerontology, Heart disease, Cardiovascular health, field-based, heart disease, Disease, 030204 cardiovascular system & hematology, Article, evidence-based review, 03 medical and health sciences, 0302 clinical medicine, risk factors, Medicine, Orthopedics and Sports Medicine, Field based, 030212 general & internal medicine, Depression (differential diagnoses), retired athletes, biology, business.industry, Athletes, cardiovascular, biology.organism_classification, medicine.disease, Obesity, Meta-analysis, business
Abstract

Background:Retirement from elite sport participation is associated with decreased physical activity, depression, obesity, and ischemic heart disease. Although engagement in physical activity through sport is recognized as cardioprotective, an estimated one-quarter of deaths in American football players are associated with cardiovascular disease (CVD), predominately in players classified as obese.Purpose:To systematically investigate the cardiovascular health profile of retired field-based athletes.Study Design:Systematic review; Level of evidence, 4.Methods:This review was conducted and reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and preregistered with PROSPERO. Four databases (PubMed, CINAHL, Embase, and Web of Science) were systematically searched from inception to October 2018 using MeSH terms and keywords. Inclusion criteria were retired field-based athletes, age >18 years, and at least 1 CVD risk factor according to the European Society of Cardiology and the American Heart Association. Review articles were not included. Control groups were not required for inclusion, but when available, an analysis was included. Eligible articles were extracted using Covidence. Methodological quality was assessed independently by 2 reviewers using the AXIS tool. The accuracy of individual study estimates was analyzed using a random-effects meta-analysis.Results:This review yielded 13 studies. A total of 4350 male retired field-based athletes from 2 sports (football and soccer; age range, 42.2-66 years) were included. Eight studies compared retired athletes with control groups. Retired athletes had elevated systolic blood pressure in 4 of 6 studies; approximately 50% of studies found greater high-density lipoprotein, approximately 80% found lower triglyceride levels, and all studies found greater low-density lipoprotein for retired athletes compared with controls. The prevalence and severity of coronary artery calcium and carotid artery plaque were similar to controls. Retired linemen had double the prevalence of cardiometabolic syndrome compared with nonlinemen.Conclusion:The overall findings were mixed. Inconsistencies in the reporting of CVD risk factors and methodological biases reduced the study quality. Retired athletes had a comparable CVD risk profile with the general population. Retired athletes with an elevated body mass index had an increased prevalence and severity of risk factors. Significant gaps remain in understanding the long-term cardiovascular effects of elite athleticism.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results